In its third year, PREVAC-UP project demonstrated exceptional adaptability amid the persistent challenges of the COVID-19 pandemic and the emergence of the Marburg and Ebola epidemics. Notable achievements included the initiation of a revaccination process in Liberia, Mali, Guinea and Sierra Leone for those who initially received a placebo or incomplete vaccination. The results of the survey conducted in Sierra Leone to assess the impact of antibody responses to Ebola vaccination was successfully published and used to inform selection of antigens for the Luminex helminth/malaria antibody assay. Beyond these accomplishments, ongoing initiatives underscore PREVAC-UP steadfast commitment to capacity-building and support to clinical research capabilities in Africa.

Please read our latest publishable summary report to learn more about the project’s progress and results !